**Supplementary Table 4. Univariate and multivariate analyses for predictors of overall survival in patients with available *KRAS* mutation status in pooled cohort**

|  |  |  |
| --- | --- | --- |
| **Variables** | **Univariate analysis** | **Multivariate analysis** |
| **HR (95% CI)** | ***P* value** | **HR (95% CI)** | ***P* value** |
| Age | 1.01 (0.99-1.03) | 0.190 |  |  |
| Gender (male) | 1.22 (0.71-2.09) | 0.471 |  |  |
| KRAS mutation | **1.64 (1.02-2.64)** | **0.041** | 1.62 (0.35-1.14) | 0.062 |
| Primary tumor location |  |  |  |  |
| (Right-sided vs. left-sided) | 1.42 (0.82-2.45) | 0.215 |  |  |
| Poor differentiation | 1.25 (0.71-2.23) | 0.441 |  |  |
| T stage (T4) | 1.10 (0.66-1.82) | 0.722 |  |  |
| Lymph node metastases | 1.10 (0.68-1.79) | 0.698 |  |  |
| Preoperative CEA | 1.00 (0.99-1.00) | 0.843 |  |  |
| Metachronous CRLM | **0.61 (0.35-1.07)** | **0.084** | 0.63 (0.98-1.14) | 0.125 |
| Number of liver metastases (> 1) | **1.23 (1.13-1.34)** | **<.001** | **1.25 (1.13-1.38)** | **<.001** |
| Largest metastasis | **1.22 (1.07-1.39)** | **0.003** | 1.17 (1.00-1.37) | 0.050 |
| LDH level | **1.00 (1.00-1.01)** | **0.065** | 1.01 (0.99-1.01) | 0.798 |

Abbreviations: HR, hazard ratio; CI, confidence interval; CRLM, colorectal liver metastases.